AB Science SA (Euronext - FR0010557264 - AB) announces today that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) granted orphan drug status to AB8939 for the ...

They said the EU should “rethink its pricing policy” in response to a drop in the proportion of money it spends on drugs compared with America. The letter – which was signed by Emma Walmsley ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. European pharmaceutical bosses have called on the EU to increase drug prices towards the much higher levels ...

Idorsia has become the first drugmaker in the EU to claim approval for ... the day after dosing than the rival drugs, because it has a shorter half-life. Belsomra has a box warning on its label ...

European pharmaceutical bosses have called on the EU to increase drug prices towards the much higher levels paid by the US, saying it will encourage innovation. In a letter to the Financial Times ...

drug developers are now able to drive more patient-facing outcomes, by supporting it with effective evidence-based decision-making across the product life cycle. At a point of increasing maturity ...

Patients are losing out on life-changing drugs for cancer and rare diseases because of Brexit, experts have warned. Treatments could be made available in the EU and US before the UK because of ...

These are known as the citric acid cycle or Krebs cycle. It is a mystery whether this is something that life developed or if it was simply co-opted from something that did not need life to exist.

ITV Granada Reports correspondent Mel Barham speaks with two families campaigning for better access to a 'life-changing' drug. The families of children with a severe genetic muscle-wasting ...